Next Phase Newsletter

A global venture capital firm founded in 1995 has offices in the Silicon Valley area and China. The firm recently closed a $750 million fund as well as a smaller $150 million fund. The firm invests exclusively in the life science sector and invests primarily in the USA and China, but will also invest in other regions such as Europe and Canada. Within China, the firm makes growth investments in companies that have existing revenues; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $10-30m, though larger investments are of interest as well; the firm’s smaller fund makes investments of typically $2-5 million, generally in financing rounds of $10 million or less. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, and blood diseases are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. The smaller fund focuses on early stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams, and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, The firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large Indian conglomerate headquartered has many subsidiary companies, several of which are involved within the life science space. Within the hospital subsidiary, the firm is particularly interested in technologies that can help reduce costs, increase access for patient populations, process data, and keep records. The firm also runs their own incubator. The firm is currently interested in Seed and Series A opportunities where they can put in $1-2 million USD. The firm also currently prefers co-investing over leading. The firm is interested in opportunities globally, but prefers if they have an interest in working in India.

The firm is particularly interested in the digital health space, specifically telemedicine and AI-based data processing. The firm is interested in these technologies as they believe that they can leverage digital health solutions in order to reduce costs within their hospital systems as well as increase the access to patients located in remote areas. The firm is also interested in Ai-based record keeping and analytic technologies as currently, medical records in India are minimal. The firm is also interested in technology related to disaster management and response. The firm is also interested in technologies that can be used to establish clinics in pharmacies as they’ve seen a trend for patients to prefer clinic visits over hospital visit in India. The firm is also particularly interested in natural remedies, specifically the use of organic and natural ingredients in Ayurveda (traditional Indian medicine). The firm also has a slight interest in genomics, but they would only be interested if a strong lead investor with genomics experience is already in place. The firm prefers investing in companies that already have proof of concept.

The firm prefers a strong management team that is dedicated and focused on seeing the project through to the end. The firm also prefers to invest alongside strong lead investors with significant experience in the field. The firm prefers to take a board seat when investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in China with offices in Beijing, Shanghai, Suzhou, Shenzhen, and Hong Kong manages about USD 1 billion in committed capital with five USD funds and five RMB funds. The firm typically invests in series A and B rounds; however the firm prefers seed or angel rounds when it comes to overseas opportunities. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies with excellent technology that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, e-Health and etc. Within therapeutics, the firm is interested in innovative drugs and novel biotechnology based therapies. Within medical devices, the firm is interested in a great range of devices and disposables that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in immuno-oncology drugs, CNS drugs, gene therapy and gene editing, digital health and AI-backed diagnostics, radiology imaging, clinical cell and molecular genetics testing, POC devices, diagnostics and genomics, and so on.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded with headquarters in Taipei City, Taiwan, with additional partners based in Silicon Valley, Korea, Singapore, and Japan, formed a fund with local and international investors. The firm has the capacity to invest in companies they identify as a strong fit, with initial investments typically in the $1-6 M range. The firm is looking for companies globally but would prefer companies that have Taiwan angle.

The firm is an opportunistic investor that currently considering Therapeutics, Medical Devices, Diagnostics, Biotechnology R&D, and Healthcare IT companies. The firm is open to many sectors in therapeutics but prefers companies that are into phase I of clinical trials or later. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled device. The firm invest in any phases in medical devices and diagnostics with a preference for those with in human data. The firm looks into any indications except orphan disease.

The firm currently will invest in privately held companies only. The firm has no specific requirements for management team. The firm can participate as either lead or co-investor and generally requests a board seat or board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact venture capital firmis dedicated to funding private, early-stage whose innovation(s) significantly help or cure patients suffering from psychiatric and/or neurological diseases. The firm will invest in Seed and Series A rounds, typically allocating $200k – 8 million USD for each deal. The firm looks for deals globally and plans to make several investments in the upcoming year immediately following the first close of the fund. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on improving the treatment or curing diseases of the central nervous system. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered.

The firm sometimes prefers to take a board seat in companies in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in California is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the company’s needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in the HIT/ Digital Health space as well as diagnostics and devices with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development. Specific areas of interest include life science tools, mental health, digital therapeutics, synthetic biology and 3D printing.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a leading electronic solutions provider looks at life sciences as one of their main focus areas. The firm focuses on strategic investments in which the corporate could bring significant value, and those that supplement the corporate’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but looks even earlier for life science-related opportunities. The firm usually invests around $5M initially and reserves capital for follow-on investment. The corporate has a global footprint, with manufacturing plants throughout USA, China, and Thailand. The firm is open to global opportunities including those in rapidly growing markets like China and India. The firm is expecting to close 3 new investments in Q1 2019.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com